SRZN
SurrozenCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
The credible bull case is that Surrozen converts from a preclinical ophthalmology story into a funded clinical-stage story: management reiterated an H2 2026 IND target for SZN-8141, ARVO provides a near-term scientific visibility point, and successful IND clearance could unlock $95.1 million of contingent PIPE proceeds that would extend runway meaningfully [#8-K-2026-03-23] [#10-K-2026-03-23].
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +1.8.
What can break
FDA clearance may not arrive by October 31, 2026, preventing the contingent second PIPE closing.
Momentum
13
Value
41
Sentiment
90
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $33.00 · Bull $45.00 · Bear $22.00
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-22 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $42.50
Why
Momentum13 · Δ7d -0.1
Value41 · Δ7d +0.0
Sentiment90 · Δ7d +1.8
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Sentiment · See AI snapshot
Momentum
13
26% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-8.5
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
90
34% active weight
Current posture
7d trendImproving
Δ7d
+1.8
Δ21d
+16.7
Why this grade
Composite grade C. Momentum 12.9 / Value 41.1 / Sentiment 90.2
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$254.96M
Beta
0.58
Shares Out
11.61M
P/E (TTM) · Derived
-0.7
P/S (TTM)
45.43
P/FCF (TTM) · Derived
-6.15
Rev YoY
+408.6%
EPS YoY
+56.7%
Gross Margin
+95.9%
Op Margin
-1055.6%
Net Debt
-$82.61M
Current Ratio
11.91
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology